Clinical Trials in Bountiful, Utah
26 recruiting
Showing 1–20 of 25 trials
Recruiting
Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Hypertriglyceridemia
Arrowhead Pharmaceuticals869 enrolled248 locationsNCT06822790
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled492 locationsNCT07517263
Recruiting
Phase 3
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Asthma
Teva Branded Pharmaceutical Products R&D LLC2,700 enrolled393 locationsNCT06052267
Recruiting
Phase 1Phase 2
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
Acne
Sanofi Pasteur, a Sanofi Company800 enrolled93 locationsNCT06316297
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled140 locationsNCT07011745
Recruiting
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
Atopic Dermatitis
Sanofi1,000 enrolled43 locationsNCT07290803
Recruiting
Phase 1
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis
Sitryx Therapeutics Ltd149 enrolled14 locationsNCT07558668
Recruiting
Phase 3
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Obesity and Overweight
Metsera, a wholly owned subsidiary of Pfizer3,500 enrolled196 locationsNCT07311850
Recruiting
Phase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Alzheimer DiseaseAgitation
Bristol-Myers Squibb600 enrolled241 locationsNCT06937229
Recruiting
Phase 3
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
ObesityOverweightType 2 Diabetes+2 more
Pfizer999 enrolled184 locationsNCT07400653
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled597 locationsNCT07181109
Recruiting
Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Cardiovascular Disease
AstraZeneca15,100 enrolled1264 locationsNCT07000357
Recruiting
Phase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Chronic Migraine
AbbVie420 enrolled61 locationsNCT06810505
Recruiting
Phase 2
A Study of DII235 in Adults With Elevated Lipoprotein(a)
Lipoprotein Disorder
Novartis Pharmaceuticals200 enrolled66 locationsNCT07235046
Recruiting
Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
DepressionBipolar I Disorder
AbbVie380 enrolled80 locationsNCT04777357
Recruiting
Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled734 locationsNCT05712200
Recruiting
Phase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Episodic Migraine
AbbVie450 enrolled98 locationsNCT05711394
Recruiting
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Atopic Dermatitis
Galderma R&D1,000 enrolled108 locationsNCT06988605
Recruiting
Phase 4
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
ModernaTX, Inc.30,000 enrolled150 locationsNCT07266558
Recruiting
Phase 3
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
COPD, Chronic Obstructive Pulmonary Disease
AstraZeneca5,000 enrolled917 locationsNCT06283966